PitchSend

FLT201: Initial Clinical Data

SRT offers an oral treatment option, but tolerability, compliance and perceived lack of efficacy limit its use Substrate reduction therapy (SRT) represents less than 20% of the market in Gaucher disease In study of 1388 patients who were either on SRT or ERT: 36% of patients on SRT switched to or went back to ERT 80% cited adverse events or lack of efficacy Physicians report compliance with 2-3x/day SRT is worse than for ERT Hughes, et al J. Clin. Med. 2022, 11, 5158. https://doi.org/10.3390/jcm11175158; FREELNE 9

View entire presentation